top of page

About Project-29

OUR MISSION

Defining Cancer Through Diagnostics

Project-29 aims to understand and define the fundamental characteristics of cancer and to develop effective tests that can detect changes to these attributes.

 

Utilizing biomarkers of disease activity will create better diagnostic understanding, improved disease tracking, and usher in a new wave individualized medicine by targeting the underlying processes and evaluating the success. 

Our Journey So Far

2022

Pilot study initiated

Project-29 initiated pilot study program with DeltaBiomarkers in Lyon, France and VDI Laboratory in Chatsworth, CA.  

2023

Project-29 is founded

Project-29 is officially launched!  Evaluating potential partners and participants, establishing a scientific advisory board, and continuing initial studies in the areas of metabolism, proliferation, inflammation, and sample logistics.

2024

Research & Recruitment

Project-29 is initiating a number of new clinical studies in coordination with our partners and researchers.  If interested, join the team!

NEWS

Project29 welcomes the following partners:

VDIlettersonly.png
Logo-delta.jpg
samplla logo.png
bottom of page